Skip to main content
Home Licenses Page 6

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies

– StrideBio receives exclusive license to novel cross-species evolved AAV vectors and an enzymatic approach for neutralizing antibody evasion – – Master Sponsored Research Agreement will support collaborative research and development of multiple novel gene…

Read More

Campus to Commercialization: Duke’s Objectives in a License

by Robin Rasor, Executive Director, OTC OTC is the office that helps connect Duke innovations with industry, entrepreneurial management, investors, and other resources to develop the partnerships necessary to create value and benefit to society.…

Read More

Crossing the Valley of Death: Tech Transfer Marketing

By Alex Mullins, Technology Marketing Associate In the field of technology transfer, we often talk about the valley of death between academic research and the commercialization of technology. This dreaded gap occurs after a researcher…

Read More

Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications

Therapies Based on Extensive Neuropathic Pain Research Conducted at UC Riverside and Duke University Target Chronic Pain at Its Source: Matrix Metalloproteinases October 28, 2020 09:10 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Releviate™ Therapeutics, a…

Read More

The Indemnification Clause: What You Need to Know

By Eric Wagner, Director, Legal Affairs   Indemnification.  A big word that doesn’t frequently come up in everyday conversation.  Unless, of course, you are a transactional attorney or a technology transfer professional. Indemnification is a…

Read More

Show Me the Money

Breaking Down the Royalty Distribution for Licensed Inventions by Mitch Dozier, Director of Operations & Finance, OTC So, your novel idea is a success–congratulations! Now that the agreement is generating or will generate revenue, you’re…

Read More

Newly published data shows positive results in KRYSTEXXA trial

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate — Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging…

Read More

AWS Announces General Availability of Amazon Braket

Amazon Braket helps developers and researchers get started with quantum computing, providing development tools, simulators, and access to a diverse set of quantum hardware. Fidelity Investments, Volkswagen, Enel, University of Waterloo, Rahko, and Qu & Co…

Read More

Uplizna launch is a ‘testament’ to NC’s prowess in drug R&D

When singer songwriter Joni Mitchell wrote “…you don’t know what you’ve got ‘til it’s gone,” she didn’t know Thomas F. Tedder, Ph.D. Tedder, the Alter Geller Professor for Research in Immunology at Duke University Medical…

Read More